Cytodigm, Inc.

10 patents currently held · Updated Nov 15, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Jun 2033

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Apr 3, 2027
The maintenance fee for Microparticles and nanoparticles having negative surface charges (US 11,771,654) comes due Apr 3, 2027. Unpaid by Oct 4, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

1 of the patents on this record was granted since Aug 17, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 10 of 10

Patent	Title	Status	Expires	Confidence
US 10,675,350	Nanoparticles of Indirubin, Derivatives Thereof and Methods of Making and Using Same In force Term ends Jun 21, 2033 · Medium confidence	In force	Term ends Jun 21, 2033	Medium confidence
US 10,780,053	Microparticles and nanoparticles having negative surface charges In force Ends no later than Dec 4, 2033 · From the USPTO record	In force	Ends no later than Dec 4, 2033	From the USPTO record
US 11,771,654	Microparticles and nanoparticles having negative surface charges In force Ends no later than Dec 4, 2033 · From the USPTO record	In force	Ends no later than Dec 4, 2033	From the USPTO record
US 12,569,441	Microparticles and Nanoparticles Having Negative Surface Charges In force Ends no later than Feb 19, 2034 · Low confidence	In force	Ends no later than Feb 19, 2034	Low confidence
US 10,702,476	Microparticle formulations of adenosine receptor antagonists for treating cancer In force Term ends Aug 14, 2038 · From the USPTO record	In force	Term ends Aug 14, 2038	From the USPTO record
US 11,439,594	Microparticles and nanoparticles having negative surface charges In force Term ends Aug 24, 2038 · From the USPTO record	In force	Term ends Aug 24, 2038	From the USPTO record
US 12,070,508	Microparticles and nanoparticles having sulfate groups on the surface In force Term ends May 28, 2040 · From the USPTO record	In force	Term ends May 28, 2040	From the USPTO record
US 12,582,612	Pharmaceutical Composition of Siglec-Binding Agents In force Term ends Oct 5, 2041 · High confidence	In force	Term ends Oct 5, 2041	High confidence
US 12,746,211	Novel Particle Composition Comprising Sialic Acid Binding Ligand In force Term ends Nov 29, 2042 · Medium confidence	In force	Term ends Nov 29, 2042	Medium confidence
US 12,303,569	Novel Lipid Nanoparticle Compositions and Uses Thereof In force Ends no later than Jun 29, 2043 · Low confidence	In force	Ends no later than Jun 29, 2043	Low confidence

Also on record, not counted in the 10: 1 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

4 no status recorded

List them